Advances in lipid nanoparticles delivering genetic medicines for solid cancers

Area of Science:

• Oncology
• Biotechnology
• Nanomedicine

Background:

• Solid tumors present significant challenges for nucleic acid delivery due to their complex tumor microenvironment (TME).
• Lipid nanoparticles (LNPs) have emerged as a key technology for delivering genetic medicines to solid tumors.
• The TME often acts as a barrier, hindering effective delivery of therapeutic nucleic acids.

Purpose of the Study:

• To review recent advancements in LNP technology for delivering genetic medicines to solid tumors.
• To discuss the challenges and future prospects of LNP-based cancer therapeutics.
• To explore diverse LNP delivery strategies targeting cancer cells, tumor vasculature, and the immune microenvironment.

Main Methods:

• Review of current literature on LNP technology and genetic medicine delivery in oncology.
• Analysis of LNP capabilities, including local/systemic administration and targeted delivery via ligand conjugation.
• Examination of various genetic medicine modalities delivered by LNPs (e.g., small non-coding RNAs, toxin genes, immunomodulatory agents).

Main Results:

• LNPs enable diverse anti-cancer effects by delivering genetic payloads directly to cancer cells or indirectly via immune modulation.
• Targeting strategies include direct suppression of oncogenic pathways, disruption of tumor vasculature, and enhancement of anti-tumor immunity.
• LNP versatility allows for tailored therapeutic approaches, addressing specific tumor characteristics and microenvironments.

Conclusions:

• LNP technology holds significant promise for developing novel oncology therapeutics against solid tumors.
• Overcoming TME barriers and optimizing LNP delivery remain critical challenges.
• Continued research into LNP design and genetic medicine payloads will expand their therapeutic potential in cancer treatment.